RNA-based therapeutics and vaccines are a new class of treatment and precaution measure for a several rare and chronic diseases such as tuberculosis, cancer, diabetes, and cardiovascular condition.
New York City, NY -- (SBWIRE) -- 12/19/2016 -- RNA plays a significant role in many biological processes thus it is considered to be a major target to develop advanced therapeutics and chemical genetic probe. In protein synthesis, RNA is a center figure that catalyzes reactions, encodes proteins, regulates gene expressions and plays another essential role in biological processes. RNA-based therapeutics and vaccines are a new class of treatment and precaution measure for a several rare and chronic diseases such as tuberculosis, cancer, diabetes, and cardiovascular condition. Ongoing research and development activities for the development of advanced biological drugs have widened the scope of therapeutic targets for a verity of diseases. This includes numerous RNA-based therapeutics under clinical trials for conditions such as genetic diseases and infectious diseases such as HIV-AIDS, as RNA controls human gene expression.
View Sample Report @ http://www.persistencemarketresearch.com/samples/12868
RNA-based therapeutics is mainly classified by its activity mechanism, and include inhibitors of mRNA translation (antisense), catalytically active RNA molecules (ribozymes), the agents of RNA interference (RNAi), and RNAs that bind protein and other molecular ligands (aptamers). RNAi was discovered in 1990 and termed post-transcriptional gene silencing as it works by turning off or silencing gene expression. Currently here are around 700 nucleic acid-based (DNA and RNA) therapeutics in the pipeline and around 60% of that are in preclinical development. Among these, 60% of pipeline products, 30% therapeutics are for the treatment of oncology. This technology has appeared to be dominant in the RNA-based therapeutics and vaccines market. Other technology such as RNA antisense, involves RNA strand synthesis, which binds to a specific mRNA in order to prevent translation. However, the issue of toxicity and drug delivery associated with RNA-based therapies is a significant challenge for commercialization. However, several new technologies have emerged to overcome these challenges, which will lead to the promising future of RNA-based therapeutics.
The RNA-based therapeutics and vaccines market is be categorized based on technology, application, disease indications and end users. The technology segment is further segmented into mRNA, siRNA, miRNA and RNA interference. The application segment is further segmented into, diseases diagnosis, therapeutics, research & development, and drug discovery. Based on disease indication, the market is segmented into, cardiovascular, infectious, respiratory, neurodegenerative, genetic and renal diseases. In this market, infectious disease segment is expected to witness highest growth rate during the forecast period due to growing incidence of AIDS and Hepatitis B. Based on the end user; the market is segmented into the pharmaceutical industry, agriculture industry, clinical research organization and other. Presently, research institutes primarily utilize RNA technology for the development of RNA drugs, thereby accounting for the largest market share.
On the basis of region presence, RNA-based therapeutics and vaccines market is segmented into five key regions: North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa. Currently, North America dominates the global market for RNA-based therapeutics and vaccines followed by Europe, owing to the high adoption of advanced technologies for drug discovery and development. Further, the rising number of cancer patients and increasing diagnosis rate of infectious diseases and increase in the prevalence of the neurodegenerative and cardiovascular disease is expected to fuel the RNA-based therapeutics and vaccines market. Moreover, a substantial investment in research and development, availability of high-end infrastructure for the development and growing government support of RNA are few of the factors responsible for the market growth. RNA-based therapeutics and vaccines market in Asia-Pacific and the Middle East and Africa is expected to register high growth due to developing healthcare infrastructure and high prevalence of infectious diseases
Request TOC (desk of content material), Figures and Tables of the report: http://www.persistencemarketresearch.com/toc/12868
Some of the major market players in RNA-based therapeutics and vaccines market globally include Sanofi S.A, Atlantic Pharmaceuticals Inc., GlaxoSmithKline plc, Novartis AG, AstraZeneca plc., Isis Pharmaceuticals, Bristol-Myers Squibb, Alnylam Pharmaceuticals Inc. Quark Pharmaceuticals, Inc, Silence Therapeutics PLC. The market is currently witnessing a number of strategic collaboration and partnership activities by pharmaceutical and biotechnology companies.